All In Biotech

Drug Trial Radar · NCT06637631

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

105

Actual

Start

Dec 10, 2024

Primary completion

Jul 30, 2026

Study completion Oct 2, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD. This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.

Conditions

  • Crohn's Disease

Interventions

  • SAR441566Drug

    Pharmaceutical form: Tablet Route of administration: Oral

  • SAR441566 matching PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving endoscopic responseTime frame: Week 12

Locations

141 sites in 24 countries. Site status is shown where the registry gives one.

  • GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020

    Sun City, Arizona

  • Bristol Hospital- Site Number : 8400007

    Bristol, Connecticut

  • Novum Research- Site Number : 8400021

    Clermont, Florida

  • Homestead Associates in Research- Site Number : 8400012

    Homestead, Florida

  • Clinical Research of Osceola- Site Number : 8400013

    Kissimmee, Florida

  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400010

    Miami Lakes, Florida

  • GCP Clinical Research- Site Number : 8400004

    Tampa, Florida

  • GI Alliance - Glenview- Site Number : 8400015

    Glenview, Illinois

  • Illinois Gastroenterology Group- Site Number : 8400011

    Gurnee, Illinois

  • University of Michigan Health System - Ann Arbor- Site Number : 8400017

    Ann Arbor, Michigan

  • Gi Alliance - Flowood- Site Number : 8400019

    Flowood, Mississippi

  • Vector Clinical Trials- Site Number : 8400001

    Las Vegas, Nevada

  • Queens Village Primary Medical Center- Site Number : 8400005

    Queens Village, New York

  • Carolina Digestive Diseases and Endoscopy Center- Site Number : 8400014

    Greenville, North Carolina

  • Frontier Clinical Research - Uniontown- Site Number : 8400009

    Uniontown, Pennsylvania

  • Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400016

    Charleston, South Carolina

  • Gastro Health & Nutrition- Site Number : 8400003

    Katy, Texas

  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400002

    Southlake, Texas

  • Washington Gastroenterology - Tacoma- Site Number : 8400008

    Tacoma, Washington

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320006

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigational Site Number : 0360002

    Sydney, New South Wales, Australia

  • Investigational Site Number : 0360001

    South Brisbane, Queensland, Australia

  • Investigational Site Number : 0360003

    Parkville, Victoria, Australia

  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760001

    Salvador, Estado de Bahia, Brazil

  • Hospital Moinhos de Vento- Site Number : 0760006

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clinicas de Porto Alegre- Site Number : 0760007

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Ernesto Dornelles- Site Number : 0760002

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pesquisare Saude- Site Number : 0760004

    Santo André, São Paulo, Brazil

  • Investigational Site Number : 1000001

    Gorna Oryahovitsa, Bulgaria

  • Investigational Site Number : 1000004

    Sofia, Bulgaria

  • Investigational Site Number : 1000005

    Sofia, Bulgaria

  • Investigational Site Number : 1240001

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240003

    Montreal, Quebec, Canada

  • Investigational Site Number : 1240005

    Québec, Quebec, Canada

  • Investigational Site Number : 1520006

    Concepción, Biobio, Chile

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.